Pharmacokinetics Interaction and Biodistribution of 5 Fluorouracil with Radiopharmaceuticals 99mTc Glutathione for Cancer Diagnostic in Mice Cancer Model

Ahmad Kurniawan, Teguh Hafidz Ambar Wibawa, Isti Daruwati, Iswahyudi Iswahyudi


Radiopharmaceutical 99mTc-Glutathione has been developed for cancer diagnostic in nuclear medicine. Interactions between chemotherapy drugs and radiopharmaceuticals can altered radiopharmaceuticals performance.  Drug interaction 5-fluorouracil (5-FU) with a radiopharmaceutical 99mTc-Glutathione in mice cancer model has been proven in pharmacokinetics study. The biological half-life distribution of 99mTc-Glutathione for cancer model mice when administrated with 5-FU become longer to 0.340±0.121h if compared with 99mTc-Glutathione. Biological half-life elimination for cancer model mice given with 99mTc-Glutathione is 72.712±2.427h. Administration of 5-FU makes the biological half-life elimination of 99mTc-Glutathione shorter to 17.030±3.459h. Biodistribution study of 5-FU continued with 99mTc-Glutathione for cancer model mice showed higher physiological uptake in the kidney was observed (39.77±2.70%ID/g) for 99mTc-Glutathione has lower uptake on kidney ( %ID/g) with p<0.05. Based on calculation on cancer model mice with colon cancer compared with muscle, shown target/non-target (T/NT) ratio 2.93 for 5-FU continued with 99mTc-Glutathione has ratio 0.42. Low ratio T/NT may affect to poor organ visualization for cancer diagnosis.  Acute toxicity study has shown drugs safety for clinical purpose. The knowledge about chemotherapy drug interaction with a radiopharmaceutical is important to have a correct diagnosis of the patient on clinical application.


5 Fluorouracil, 99mTc-Glutathione, Drug-Radiopharmaceutical Interaction, Cancer Diagnostic, Nuclear Medicine

Full Text:



Bray F., Ferlay J., Soerjomataram I., Siegel RL., Torre LA., Jemal A. 2018. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal For Clinicians, 68(6), 394-424.

Ercan MT., Senekowitsch-Schmidtke R., Bernatz, S., 1999. Biodistribution of 99m Tc-glutathione in mice with osteosarcoma : effect of gamma irradiation on tumour uptake. Research in Experimental Medicine, 359–367.

Focaccetti C., Bruno A., Magnani E., Bartolini D., Principi E., Dallaglio K., Albini A. 2015. Effects of 5-fluorouracil on morphology, cell cycle, proliferation, apoptosis, autophagy and ROS production in endothelial cells and cardiomyocytes. PloS one, 10(2).

Kim DW., Kim WH., Kim MH., Kim CG., Oh CS., Min JJ. 2014. Synthesis and evaluation of Tc-99m DTPA–glutathione as a non-invasive tumor imaging agent in a mouse colon cancer model. Annals of nuclear medicine, 28(5), 447-454.

Longley DB., Harkin DP., Johnston PG. 2003. 5-Fluorouracil : Mechanisms of Action and Clinical Strategies. Nature review cancers, 3(5), 330–338.

Miura K., Kinouchi M., Ishida K., Fujibuchi W., Naitoh T., Ogawa H., Shibata C. 2010. 5-fu metabolism in cancer and orally-administrable 5-fu drugs. Cancers, 2(3), 1717-730.

Mahendra I., Daruwati I., Halimah I., Pajrin SR. 2018. Pharmacokinetics Interaction of Non-Steroid Anti Inflammatory Drugs to 99m Tc-MDP Radiopharmaceuticals for Bone Imaging and Its Biodistribution. Atom Indonesia, 44(3), 173-177.

Nurlaila Z., Sriyani ME. 2010. Formulasi radiofarmaka 99mTc-glutation untuk diagnosis kanker. Jurnal Sains dan Teknologi Nuklir Indonesia, 11(2).

Perales JLG., Martínez AA. 2013. A portable database of adverse reactions and drug interactions with radiopharmaceuticals. Journal of nuclear medicine technology, 41(3), 212-215.

Razaq T., Nisar H., Roohi S., Shehzad A., Ahmad I. 2017. Administration of 99mTc-DTPA in combination with doxorubicin alters the radiopharmaceutical biodistribution in rats. Iranian Journal of Nuclear Medicine, 25(2), 122-128.

Santos-Oliveira R., Smith SW., Carneiro-Leão AMA. 2008. Radiopharmaceuticals drug interactions: a critical review. Anais da Academia Brasileira de Ciências, 80(4), 665-675.

Saha GB. 2010. Radiopharmaceuticals and methods of radiolabeling. In Fundamentals of nuclear pharmacy (pp. 83-113). Springer, New York, NY.

Shuryak I., Dadachova E. 2015. New Approaches for Modeling Radiopharmaceutical Pharmacokinetics Using Continuous Distributions of Rates. Journal of Nuclear Medicine, 56(10), 1622-1628.

Silveira MB., Ferreira SM., Nascimento LT., Costa FM., Mendes BM., Ferreira AV., Mamede M. 2016. Preclinical acute toxicity, biodistribution, pharmacokinetics, radiation dosimetry and microPET imaging studies of [18F] fluorocholine in mice. Applied Radiation and Isotopes, 116, 92-101.

Tanaka T., Kohno H., Suzuki R., Yamada Y., Sugie S., Mori H. 2003. A novel inflammation‐related mouse colon carcinogenesis model induced by azoxymethane and dextran sodium sulfate. Cancer science, 94(11), 965-973.

Wahidin M., Noviani R., Hermawan S., Andriani V., Ardian A., Djarir H. 2012. Population-based cancer registration in Indonesia. Asian Pacific Journal of Cancer Prevention, 13(4), 1709-1710.

Wongso H., Zainuddin N., Iswahyudi I. 2013. Biodistribution and Imaging of The 99m Tc-Glutathione Radiopharmaceutical in White Rats Induced with Cancer. Atom Indonesia, 39(3), 106-111.

Zhang Y., Huo M., Zhou J., Xie S. 2010. PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Computer methods and programs in biomedicine, 99(3), 306-314.



  • There are currently no refbacks.

Copyright (c) 2019 Indonesian Journal of Pharmacy

Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Indonesian J Pharm indexed by:

analytics View My Stats